Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease

NCT ID: NCT00221026

Last Updated: 2016-10-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-12-31
• Study Completion Date: 2006-06-30

Brief Summary

his study will explore the safety and activity of ECP treatment with UVADEX in inducing a clinical response (i.e., a CDAI decrease greater than or equal to 100 from baseline and/or a CDAI < 150) over a 12-week period in moderately active Crohn's disease (CDAI greater than or equal to 220 to < 450) patients who are refractory or intolerant to immunosuppressants and/or anti-TNF agents. This study will also assess response to continued treatment during a 12-week Extension Period in patients who have a clinical response at Week 12 of the Treatment Period and elect to participate in the Extension Period.

Conditions

Crohn's Disease

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

drug

ECP + Uvadex given for 12 weeks.

Group Type: EXPERIMENTAL

Methoxsalen +ECP

Intervention Type: DRUG

ECP + Uvadex given at weeks 1-12 weeks.

Extracorporeal Photopheresis

Intervention Type: PROCEDURE

ECP given at weeks 1 through 12.

Interventions

Methoxsalen +ECP

ECP + Uvadex given at weeks 1-12 weeks.

Intervention Type: DRUG

Extracorporeal Photopheresis

ECP given at weeks 1 through 12.

Intervention Type: PROCEDURE

Other Intervention Names

Uvadex; uvadex+ECP

Eligibility Criteria

Inclusion Criteria

• Signed and dated informed consent must be obtained prior to conducting any study procedure.
• Patients must be greater than or equal to 18 years of age.
• Patients must have a body weight greater than or equal to 40 kg (88 lb).
• Patients must have had Crohn's disease for at least 6 months duration (with colitis, ileitis, or ileocolitis) confirmed by radiography or endoscopy.
• Patients must have a CDAI greater than or equal to 220 to < 450.
• Patients must have a CRP concentration > 10.0 mg/L (1.0 mg/dL) or evidence of active inflammatory luminal Crohn's disease as demonstrated by superficial and/or deep ulcerations, pseudopolyps, and/or ulcerated stenosis on colonoscopy within 8 weeks of screening.
• Patients who are receiving corticosteroids must be on a prednisone equivalent dose less than or equal to 25 mg/day or an oral (PO) budesonide dose less than or equal to 9 mg/day.
• Patients who are receiving any of the following concomitant Crohn's disease medications must have been on a stable dose of these medications for the specified period of time PRIOR TO confirmation of eligibility (this time period may include screening): aminosalicylates, antibiotics, and immunosuppressants (i.e., 6 MP, MTX, or AZA) for at least 4 weeks; corticosteroids or PO budesonide for at least 2 weeks; anti-TNF agents (i.e., infliximab or adalimumab) for at least 8 weeks.
• Patients who have failed treatment with immunosuppressants and/or anti-TNF agents.
• Patients who have fistulae are permitted, provided: patients have predominantly luminal Crohn's disease, and fistulae are not associated with abscess formation.
• Patients must have a platelet count greater than or equal to 50,000/microL (50.0 x 109/L).
• Female patients must be: postmenopausal, surgically incapable of bearing children, or practicing an acceptable method of birth control (acceptable methods include hormonal contraceptives, intrauterine device, and spermicide and barrier). Abstinence or partner/spouse sterility may also qualify at the Investigator's discretion. If a female patient is of childbearing potential, she must have a negative urine pregnancy test at screening. Male patients must also commit to using adequate contraceptive precautions (condoms). All patients (both males and females of childbearing potential) must commit to using adequate contraceptive precautions throughout their participation in the study and for at least 3 months following their last ECP treatment
• Patients must be able and willing to comply with all study procedures.

Exclusion Criteria

• Patients who are concomitantly using biologic agents other than anti-TNF agents; cyclosporine (CSA), tacrolimus (FK506), mycophenolate mofetil (MMF), or investigational Crohn's disease therapies.
• Patients who, in the opinion of the Investigator, may not be able to remain on a stable dose of a concomitant Crohn's disease medication during the 12-week Treatment Period.
• Patients with currently symptomatic untreated diarrhea, due to conditions other than inflammatory Crohn's disease (e.g., bacterial or parasitic gastroenteritis, bile salt diarrhea, or bacterial overgrowth).
• Patients with symptomatic intestinal strictures.
• Patients with stomas.
• Patients with other local manifestations of Crohn's disease such as abscesses, or other disease manifestations for which surgery might be indicated, or which might preclude utilization of a CDAI to assess response to therapy (such as "short gut" syndrome).
• Patients who are unable to tolerate the extracorporeal volume shifts associated with ECP treatment due to the presence of any of the following conditions: uncompensated congestive heart failure, pulmonary edema, severe chronic obstructive pulmonary disease, severe asthma, renal failure, or hepatic failure.
• Patients receiving total parenteral nutrition, as the sole source of nutrition, within 3 weeks of screening.
• Female patients whose hemoglobin (Hgb) is < 8.5 g/dL or male patients whose Hgb is < 10.0 g/dL at screening.
• Patients with a poor tolerability of venipuncture or a lack of adequate venous access for required treatments and blood sampling.
• Patients who have a known hypersensitivity or allergy to psoralen (methoxsalen).
• Patients who have a known hypersensitivity or allergy to both heparin and citrate products.
• Female patients who are pregnant and/or lactating.
• Patients who have been enrolled in any investigational study for the treatment of Crohn's disease within 4 weeks of enrollment for non biologic therapies and within 8 weeks of enrollment for biologic therapies.
• Patients who have any of the following: a co-existing melanoma, squamous cell skin carcinoma, aphakia, photosensitive disease (e.g., porphyria, systemic lupus erythematosus, or albinism), a white blood cell count > 25,000 mm3, a previous splenectomy, or a clinically significant coagulation disorder.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

ICON plc

INDUSTRY

Sponsor Role: collaborator

Mallinckrodt

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

NIH

Bethesda, Maryland, United States

Metropolitian Gastroenterology Group

Chevy Chase, Maryland, United States

Morristown Memorial Hospital

Morristown, New Jersey, United States

Mount Sinai Medical Center

New York, New York, United States

General Hospital of Vienna

Vienna, , Austria

Hospital Erasme/ULB

Brussels, , Belgium

UZ Leuven

Leuven, , Belgium

Universitat St Josef

Bochum, , Germany

Krankenhaus Duren gem.GmbH

Düren, , Germany

Universitatsklinik Essen

Essen, , Germany

Universitatsklinikum

Jena, , Germany

Universitatsklinikum Mannheim

Mannheim, , Germany

University Hospital Munich-Grosshadem

Munich, , Germany

Klinikum Oldenberg

Oldenburg, , Germany

Medizinische Universitatsklinik Ulm

Ulm, , Germany

Countries

United States; Austria; Belgium; Germany

Other Identifiers

CD-2

Identifier Type: -

Identifier Source: org_study_id

NCT00105261

Identifier Type: -

Identifier Source: nct_alias